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Abstract
Mesothelial-to-mesenchymal transition (MMT) is an auto-regulated physiological process of tissue repair that in
uncontrolled conditions such as peritoneal dialysis (PD) can lead to peritoneal fibrosis. The maximum expression of
peritoneal fibrosis induced by PD fluids and other peritoneal processes is the encapsulating peritoneal sclerosis (EPS) for
which no specific treatment exists. Tamoxifen, a synthetic estrogen, has successfully been used to treat retroperitoneal
fibrosis and EPS associated with PD. Hence, we used in vitro and animal model approaches to evaluate the efficacy of
Tamoxifen to inhibit the MMT as a trigger of peritoneal fibrosis. In vitro studies were carried out using omentum-derived
mesothelial cells (MCs) and effluent-derived MCs. Tamoxifen blocked the MMT induced by transforming growth factor
(TGF)-b1, as it preserved the expression of E-cadherin and reduced the expression of mesenchymal-associated molecules
such as snail, fibronectin, collagen-I, a-smooth muscle actin, and matrix metalloproteinse-2. Tamoxifen-treatment preserved
the fibrinolytic capacity of MCs treated with TGF-b1 and decreased their migration capacity. Tamoxifen did not reverse the
MMT of non-epitheliod MCs from effluents, but it reduced the expression of some mesenchymal molecules. In mice PD
model, we demonstrated that MMT progressed in parallel with peritoneal membrane thickness. In addition, we observed
that Tamoxifen significantly reduced peritoneal thickness, angiogenesis, invasion of the compact zone by mesenchymal
MCs and improved peritoneal function. Tamoxifen also reduced the effluent levels of vascular endothelial growth factor and
leptin. These results demonstrate that Tamoxifen is a therapeutic option to treat peritoneal fibrosis, and that its protective
effect is mediated via modulation of the MMT process.
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Introduction
In peritoneal dialysis (PD), the peritoneal membrane (PM) is
exposed to bio-incompatible dialysis solutions, with high content of
glucose, which can cause peritoneal injury when associated with
peritoneal incidents like repeated episodes of peritonitis or
hemoperitoneum [1], [2], [3]. Progressive fibrosis, angiogenesis
and ultimately, ultrafiltration failure, are some characteristics of
the so-called sclerotic peritonitis syndromes [4]. Several pathologic
factors, such as inflammatory mediators, high glucose content, the
presence of glucose degradation products, and low pH can induce
peritoneal mesothelial cells (MCs) to lose certain epithelial
characteristics and progressively acquire a fibroblast-like pheno-
type soon after initiation of PD. This so-called mesothelial-to-
mesenchymal transition (MMT) serves as a trigger for peritoneal
fibrosis and angiogenesis, via up-regulation of transforming growth
factor (TGF)-b1 and vascular endothelial growth factor (VEGF),
respectively [5], [6]. As such, MMT is considered an important
potential therapeutic target in peritoneal deterioration [7], [8].
Encapsulating peritoneal sclerosis (EPS) is a severe form of
peritoneal fibrosis characterized by intestinal encapsulation
through the deposition of excessive matrix components that
subsequently may lead to obstruction of the intestinal tract.
Although rare, EPS is a serious complication of PD for which no
specific and definitive treatment exists. However, peritoneal
resting, steroids, immunosuppressive agents and Tamoxifen have
been used previously as therapeutic approaches with divergent
results [9], [10], [11], [12]. Tamoxifen is an estrogen receptor
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modulator used for the treatment of breast cancer [13]. Tamoxifen
can also affect the activity of TGF-b1 and has been shown to be
effective in fibrotic diseases as retroperitoneal fibrosis. In this
context, in 1991 Clark et al. reported a dramatic reduction of
peritoneal fibrosis and mortality in two patients diagnosed with
retroperitoneal fibrosis and treated orally with Tamoxifen [14].
Given the high morbidity and mortality associated with EPS, the
lack of specific treatments, and the therapeutic potential of
Tamoxifen [14], in 1992 we started the first clinical study to
analyze the effects of oral Tamoxifen treatment (20 mg every 12 h)
in PD patients suffering this peritoneal complication. Their
evolution was compared with a historic EPS control group
collected between 1980 and 1992. We found a significant
reduction in surgical abdominal complications, hospital admission
rates and mortality in comparison with the non-treated patients
[15]. Similar results were obtained in other clinical studies using
Tamoxifen to treat EPS [16].
These clinical experiences and the information provided by
other investigators in regard to the anti-fibrotic and anti-
angiogenic effects associated to Tamoxifen-treatments [16], [17],
[18], [19] encouraged us to study the molecular mechanisms
involved in the peritoneal protective effects of Tamoxifen in more
detail. Thus, we have specifically analyzed the effect of Tamoxifen
on the MMT of MCs, both in vitro and in an animal experimental
model, given the central role of this process in the initiation and
progression of peritoneal injury in PD patients [5], [7], [8].
We found that Tamoxifen blocked and reverted the MMT of
MCs in vitro and partially reverted the mesenchymal characteristics
of effluent-derived MCs. In mice exposed to PD fluid, Tamoxifen
ameliorated peritoneal thickness and angiogenesis, and decreased
submesothelial MMT.
Materials and Methods
Culture of omentum and effluent-derived MCs and
treatments
MCs were obtained from omental samples taken from patients
undergoing elective abdominal surgery and from the effluents of
PD patients as described previously [5], [20], [21]. The purity of
the omentum- and effluent-derived MCs cultures was determined
by the expression of the standard mesothelial markers: intercellular
adhesion molecule (ICAM)-1, calretinin and cytokeratins. These
MCs cultures were negative for von-Willebrand factor and CD45,
ruling out any contamination by endothelial cells or macrophages
[5], [20], [21]. To induce MMT in vitro, omentum-derived MCs
were seeded on wells coated with collagen I (50 mg/mL, Roche
Diagnostics GmbH, Mannheim, Germany) and treated for
different time points (12 to 48 hours) with human-recombinant
TGF-b1 (1 ng/mL, R&D Systems Inc, Minneapolis, MN.), a
commonly used in vitro model of MMT [5], [22], [23], [24]. Where
indicated Tamoxifen (Lilly Research Laboratories, Indianapolis,
Indiana, USA) was administered at concentrations of 3 and 6 mM,
as has been referred by others [25], [26], [27], [28]. Effluent-
derived MCs that have undergone a MMT (as determined by non-
epitheliod morphology, by low expression of E-cadherin and by
up-regulated expression of mesenchymal markers) were also
administrated with different doses of Tamoxifen (3, 6, and
10 mM) and analyzed at 48 hours.
To evaluate the ability of Tamoxifen to revert the MMT in vitro,
omentum-MCs were stimulated with TGF-b1 during 48 hours
and then subdivided into four groups. In group 1, MCs were
treated with TGF-b1 for additional 48 hours (total 96 hours). In
group 2, TGF-b1 was withdrawal and the cells were left untreated
during the next 48 hours to observe the spontaneous evolution of
MMT. In the groups 3 and 4, the cells were treated with
Tamoxifen (6 or 10 mM), after TGF-b1 withdrawal, during
48 hours. At the end of experiment, MCs were morphologically
analyzed and the expression of E-cadherin was determined by
quantitative RT-PCR.
The present study adjusts to the Declaration of Helsinki and it
was approved by the Ethic Committee of ‘‘Hospital Universitario
de la Princesa’’ (Madrid, Spain). Informed written consent was
obtained from all of the patients (PD effluent and omentum
donors).
Western blot, quantitative RT-PCR, enzyme-linked
immunoassays, and migration assays
For western blotting, MCs cultures were lysed in a buffer
containing 1% sodium deoxycholate and 0.1% sodium dodecyl
sulfate (SDS). The total protein was quantified using a protein
assay kit (Bio-Rad, Hercules, CA). Total cell protein (50 mg) was
resolved on 8–10% SDS-polyacrylamide gels and transferred to
nitrocellulose membranes, which were then blocked with fat-free
milk and probed with specific antibodies against a-ER (Santa Cruz
Biotechnology Inc, Santa Cruz, CA), E-cadherin, a-SMA,
collagen I, fibronectin, MMP-2 and tubulin (Sigma-Aldrich, Inc,
St Louis MO). These antibodies were detected with a peroxidase
conjugated goat anti-mouse IgG antibody (BD Biosciences,
Franklin Lakes, NJ) and visualized by enhanced chemilumniscence
(ECL detection kit, Amersham Biosciences, Freiburg, Germany).
Images of the blots were acquired with a LAS-1000 Charge
Coupled Device camera (Fujifilm, Cedex, France).
For quantitative RT-PCR analysis, MCs were lysed in TRI
Reagent (Ambion Inc, Austin, TX), and RNA was extracted as
fabricant instructions. Complementary-DNA was synthesized
from 2 mg of total RNA by reverse transcription (RNA PCR
Core Kit, Applied Biosystems Inc, New Jersey). Quantitative PCR
was carried out in a Light Cycler 2.0 using a SYBR Green Kit
(Roche Diagnostics GmbH) and specific primers sets for Snail, E-
cadherin and histone H3. Samples were normalized with respect
to the value obtained for H3. The primer sets employed for Snail,
E-cadherin and H3 have been previously described [22].
To evaluate the fibrinolytic capacity of MCs isolated from
omentum and from PD effluent, the concentration of plasminogen
activator inhibitor type-1 (PAI-1), tissue-type plasminogen activa-
tor (tPA), urokinase-type plasminogen activator (uPA) and
urokinase-type plasminogen activator receptor (uPAR) was mea-
sured in culture supernatants by ELISA kits (R&D Systems Inc).
To study migration, 56104 MCs that were either treated or not
with TGF-b1 and different doses of Tamoxifen for 24 hours, were
re-suspended in 100 mL of M199 supplemented with 0.1% human
serum albumin (HSA) and plated in the upper chamber of
polycarbonate membrane transwell units (6.5 mm diameter,
5 mm-diameter pore size; Costar, Corning, NY), while 600 mL of
M199 with 0.1% HSA and recombinant epidermal growth factor
(10 ng/mL) was placed in the lower chamber. MCs were allowed
to migrate for 24 hours in an atmosphere of 5% CO2 at 37uC.
The cells that had migrated were recovered from the underside of
the membrane, detached with trypsin-EDTA (0.05%), washed and
resuspended in M199 medium. Finally, the cells were stained with
propidium iodide and counted over 1.5 min by flow cytometry
(FACS Canto II cytometer; BD Biosciences).
Effect of Tamoxifen on cell cycle, apoptosis, and wound
healing
Given that the regulation of estrogen receptor has been
implicated in cell proliferation and apoptosis [29], [30] we
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analyzed if Tamoxifen affected the cell cycle and apoptosis in
MCs. To analyze the effect of Tamoxifen on cell cycle profile,
omentum MCs were grown with fetal calf serum 20% and treated
with different doses of Tamoxifen (3, 6, and 10 mM) for 48 h. Cells
were trypsinized, pelleted, and fixed with 70% cold ethanol for
30 min. After washing, samples were suspended in PBS and an
equal volume of propidium iodide solution, containing 200 mg/
mL RNase (Sigma Aldrich), 20 mg/mL propidium iodide (Sigma
Aldrich), and 0.1% Triton X-100 in PBS, was added to the cell
suspension for 30 min at room temperature. A FACS Calibur flow
cytometer (BD Bioscience) was used to analyze DNA content;
emitted light was measured at 675 nm.
To analyze the effect of Tamoxifen on apoptosis, MCs were
cultured to subconfluence in 12-well plates for 24 hours. Cells
were pre-incubated with Tamoxifen (3, 6, and 10 mM) and treated
with 100 nM Staurosporine (STS) during 24 hours [31]. For
quantification of cell death, cells were harvested by pooling non-
adherent cells with adherent cells, which were detached by gentle
trypsinization. Apoptosis was quantified by flow cytometry
assessment of DNA content using Cellquest software (BD
Biosciences).
To test the effect of Tamoxifen on wound repair capacity of
MCs, a wound healing experiment was performed with cells
treated or not with different doses of Tamoxifen (3 and 6 mM).
Confluent culture of MCs from omentum were subjected to
mechanical injury with an adapted cell scraper approximately
1500 mm in width and photographed every twelve hours during
72 hours.
Peritoneal dialysis fluid exposure model in mice
A total of 61 female C57BL/6 mice aged between 12 and 16
weeks old were used in this study (Charles River S.A., Barcelona,
Spain). The experimental protocol used was in accordance with
the National Institutes of Health Guide for Care and Use of
Laboratory Animals and was approved by the Animal Ethics
Committee of the ‘‘Unidad de Cirugı´a Experimental’’ of ‘‘Hospital
Universitario la Paz’’. PD fluid or saline solution were instilled via
a peritoneal catheter connected to an implanted subcutaneous
mini access port (Access Technologies, Skokie, IL, USA) as
previously described [22], [23].
During the first week after surgery, the animals implanted with
a peritoneal access port received 0.2 mL of saline with 1 IU/mL
heparin. Thereafter, during a 4-week period, 10 mice were daily
instilled with 1.5 mL of saline solution (Control group), 17 mice
were daily instilled with 1.5 mL of standard PD fluid (PDF group)
composed of 4.25% glucose and buffered with lactate (Stay Safe;
Fresenius, Bad Homburg, Germany) and 19 mice were treated
with oral Tamoxifen [32], [33] and daily instilled with 1.5 mL of
standard PD fluid (PDF + Tamoxifen group).
Figure 1. Tamoxifen increases a-ER expression in MCs isolated from omentum and PD effluent. Omentum-derived MCs were treated or
not for 24 hours with TGF-b1 in the presence of different doses of Tamoxifen (0, 3 and 6 mM). (A) Western blot analysis shows that MCs express a-ER
and that its expression is up-regulated by Tamoxifen in cooperation with TGF-b1. (B) Epithelioid and non-epithelioid MCs isolated from PD effluent
showed up-regulation of a-ER expression. After Tamoxifen 6 mM administration, both group of cells showed a further increase of a-ER expression. A
representative experiment is shown. (C and D) Bars in graphic represent means 6 SE of three independent experiments.
doi:10.1371/journal.pone.0061165.g001
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Tamoxifen was diluted in water (1.5 mg/kg/day in 15 mL of
volume). This volume was orally administered to mice using a
pipette and a gastric tube. Three animals of the PDF group, two
from PDF + Tamoxifen group and one from Control group were
not used in the final analysis, being the main causes of drop-outs
catheter port infection or traumatic catheter removal (Control
group, n = 9; PDF group, n = 14 and PDF + Tamoxifen group,
n = 17). A peritoneal equilibrium test was performed during the
last day of treatments. Mice were instilled with 2 mL of PD
solution and after 30 min, animals were anaesthetized with
isoflurane (MTC Pharmaceuticals, Cambridge, ON, Canada)
and sacrificed to recover the total peritoneal volumes [22], [23].
Parietal peritoneum pieces were obtained from the contralateral
side of the implanted catheter. Food and water were provided ad
libitum to the animals.
To evaluate the time course progression of MMT and
peritoneal fibrosis, we made an additional experiment in which
15 mice were daily instilled with 1.5 mL of standard PD fluid and
sacrificed at 7, 15, or 30 days; five mice were included in each time
point. Submesothelial MMT markers and peritoneal thickness
were measurement as described below.
Histological analysis of peritoneal samples and effluent
growth factors measurement
For histochemical analysis, parietal peritoneum tissues were
routinely fixed in Bouin’s liquid and embedded in paraffin to
obtain serial tissue sections 3–4 mm thick. Deparaffinized sections
were stained with Masson’s trichrome solution to analyze the
histological characteristics of each specimen. The thickness of
submesothelial tissue was determined by blinded microscope
analysis using a metric ocular, and was expressed as the mean of
10 independent measurements for each animal.
For immunofluorescence analysis, cryostat sections (5 mm) were
stained with antibodies to visualize vasculature (CD31; Serotec,
Oxford, UK), mesothelial cells (Pan-Cytokeratin; Sigma-Aldrich),
and pathologic fibroblasts (FSP1; Dako). The frozen sections were
fixed for 15 minutes in 4% formaldehyde in PBS, and blocked with
10% horse serum for 1 hour in PBS with 0.3% Triton X-100. First
antibodies were incubated in PBS with 0.1% Triton X-100
overnight at 4uC. After 3 washing steps, secondary Alexa-labelled
antibodies were incubated during 90 minutes at room tempera-
ture. After another washing process, the preparations were
mounted with a 4,6-diamidino-2-phenylindole (DAPI) nuclear
stain (Vectashield; Vector Laboratories). Negative controls for
immunofluorescence staining were conducted using 10% rabbit
serum instead of primary antibody. Images were analysed by
computerized digital image analysis (AnalySIS, Soft Imaging
System). Number of cells with single or double positive staining
was counted and was expressed as the mean of 10 independent
measurements for each animal [22].
The amounts of VEGF, TGF-b1 and Leptin in the peritoneal
effluents were determined by ELISA-based assays, according to
the manufacturers instructions (Bender MedSystems, Vienne,
Austria; BD Biosciences Pharmingen, San Diego, CA; and
Mediagnost, Reutlingen, Germany, respectively).
Statistical analysis
Results are presented as mean 6 SE in bars graphics and as
25th and 75th percentiles, median, minimum, and maximum
values in box plot graphics. Lineal regression analysis was used to
evaluate the correlation between submesothelial MMT and
peritoneal thickness (Spearman test). The data groups were
compared with ANOVA one way and Mann–Whitney rank sum
U-test using the SPSS statistic package version 14.5 (Chicago, IL)
and GraphPad Prism version 4.0 (La Jolla, CA). P,0.05 was
considered statistically significant.
Results
Tamoxifen blocks and reverts MMT in vitro and partially
reverts the mesenchymal phenotype of effluent-derived
MCs
We first analyzed whether omentum-derived MCs expressed
estrogen receptor alpha (a-ER), and how its expression was
affected by TGF-b1 and/or different doses of Tamoxifen (3 and
6 mM). Tamoxifen increased the expression of a-ER in a dose-
dependent manner and in cooperation with TGF-b1; a six-fold
increase of a-ER expression was observed. Similarly, epithelioid
and non-epithelioid MCs from PD effluents showed up-regulated
expression of a-ER that further increased upon Tamoxifen
administration (Figure 1). Then we analyzed if Tamoxifen affected
the cell cycle/apoptosis and the wound repair capacity of MCs.
Figure 2. Tamoxifen blocks the TGF-b1-induced MMT but does
not revert the mesenchymal morphology of effluent-derived
MCs. (a to f) Omentum-derived MCs were treated or not for 48 hours
with TGF-b1 in the presence of different doses of Tamoxifen (0, 3 and
6 mM). Phase-contrast microscopy shows that Tamoxifen treatment
prevents the morphological change induced by TGF-b1. (g and h)
Effluent-derived MCs with non-epithelioid morphology were either left
untreated or treated with Tamoxifen (10 mM) during 48 hours. Phase-
contrast microscopy shows that Tamoxifen does not revert the
morphology of MCs to an epithelioid phenotype.
doi:10.1371/journal.pone.0061165.g002
Tamoxifen and Peritoneal Membrane Failure
PLOS ONE | www.plosone.org 4 April 2013 | Volume 8 | Issue 4 | e61165
Figure 3. Tamoxifen blocks TGF-b1-induced MMT of MCs. Omentum-derived MCs were treated or not with 1 ng/mL TGF-b1 for 24 or
48 hours, in the presence of different doses of Tamoxifen (0, 3 and 6 mM). (A) Western blot analyses show that Tamoxifen treatment prevents TGF-b1-
induced E-cadherin down-regulation as well as a-SMA, collagen I, fibronectin and MMP-2 up-regulation. A representative experiment is shown. (B to
F) The experiments were repeated at least five times and results are depicted as means 6 SE. The expressions of E-cadherin (B) and MMP-2 (F) were
analyzed at 24 hours, whereas the expressions of a-SMA (C), collagen I (D) and fibronectin (E), were analyzed at 48 hours of treatments. (G) Analysis
of the migration capacity in transwell units demonstrates that Tamoxifen (6 mM) reduces the TGF-b1-indued migratory capacity of MCs to basal levels.
The experiments, made in triplicates, were repeated at least four times. Box plots represent the median, minimum and maximum values, as well as
the 25th and 75th percentiles.
doi:10.1371/journal.pone.0061165.g003
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The cells did not display significant differences in cell cycle
between control and Tamoxifen treatments (Table S1). Moreover,
Tamoxifen protected MCs from apoptotic death induced by
Staurosporine. These results indicated that Tamoxifen was not
cytotoxic for MCs and that rather, it produced an anti-apoptotic
effect in these cells (Figure S1). Tamoxifen treatment did not
influence significantly wound healing capacity of MCs (Figure S2).
Given the anti-fibrotic effects of Tamoxifen in retroperitoneal
fibrosis and EPS and that the MMT of MCs is an important
process in peritoneal deterioration we examined the effect of
Tamoxifen on MMT of MCs. Treatment of omentum MCs with
Tamoxifen (3 and 6 mM) blocked the TGF-b1-induced morpho-
logical change (Figure 2) and down-regulation of E-cadherin
(Figures 3A and 3B). In addition, Tamoxifen interfered the TGF-
b1-mediated up-regulation of MMT-associated proteins including
a-smooth muscle actin (a-SMA), the matrix components collagen I
and fibronectin, and matrix metalloproteinse-2 (MMP-2)
(Figures 3C to 3F). During the MMT process the MCs acquire
increased migratory capacity, thus we explored the effect of
Tamoxifen on TGF-b1-induced migration. As shown in Figure 3G,
Tamoxifen (6 mM) reduced the migratory capacity of MCs treated
with TGF-b1 to basal levels.
To further demonstrate the MMT-blocking properties of
Tamoxifen, we analyzed the effect of this drug on the transcription
of E-cadherin-encoding mRNA. Tamoxifen treatments (3 and
6 mM) prevented TGF-b1-induced E-cadherin mRNA down-
regulation (Figure 4A). Conversely, Tamoxifen blocked the
induction by TGF-b1 of Snail mRNA, the main transcriptional
repressor of E-cadherin (Figure 4B).
To analyze whether Tamoxifen was able to revert the MMT in
vitro, omentum-MCs were stimulated with TGF-b1 during
48 hours and then the cells were either left untreated or treated
with Tamoxifen (6 or 10 mM) during the next 48 hours. A group
subjected to TGF-b1 stimulation for 96 hours was also included.
The cells subjected to TGF-b1 stimulation for 48 and 96 hours
showed a pronounced fibroblast-like shape and down regulation of
E-cadherin (Figures 5A and 5B). After TGF-b1 withdrawal, the
recovery of the epithelioid morphology was more evident in cells
treated with Tamoxifen (6 or 10 mM) than in cells left untreated
(Figure 5A). In addition, there was a partial re-expression of E-
cadherin in cells treated with Tamoxifen (6 mM) after TGF-b1
withdrawal but not in cells left untreated (Figure 5B).
By contrast, Tamoxifen treatments were unable to revert the
spindle-like shape of effluent-derived MCs to an epithelioid
morphology (Figure 2) and to re-induce the expression of E-
cadherin (Figures 6A and 6B) even at high doses, 6 and 10 mM, of
the drug. However, the expression of certain MMT-associated
molecules including a-SMA, collagen I, fibronectin, and MMP-2
could be down-regulated by Tamoxifen, but only at high doses of
the drug (Figures 6C to 6F). In agreement with the lack of effect of
Tamoxifen on the expression of E-cadherin, this drug was unable
to inhibit the expression of Snail-encoding mRNA at any
concentration tested (Figure 6G).
Tamoxifen preserves the fibrinolytic property of MCs
treated with TGF-b1
The fibrinolytic capacity of MCs is essential to maintain the
production/degradation balance of matrix components to avoid
the formation of peritoneal adherences. Treatment of omentum
MCs with TGF-b1 inhibited the expression of the fibrinolytic
factors tissue-type plasminogen activator (tPA), urokinase-type
plasminogen activator (uPA) and uPA receptor (uPAR). Interest-
ingly, treatments with different doses of Tamoxifen restored the
basal levels of these factors or even increased their synthesis above
basal levels (Figures 7A to 7C). TGF-b1-mediated induction of
MMT was also accompanied by increased expression of plasmin-
ogen activator inhibitor-1 (PAI-1), a strong anti-fibrinolytic
molecule, which was not affected by Tamoxifen (Figure 7D).
However, the PAI-1/tPA-ratio, a commonly used marker to
determine the decline of fibrinolytic capacity, increased during
TGF-b1-induced MMT and returned to basal ratio upon
Tamoxifen treatments (Figure 7E).
In contrast, treatment of transdifferentiated MCs from PD
effluent with Tamoxifen did not change the PAI-1/tPA-ratio,
indicating that these cells retained low fibrinolytic capacity (Figure
S3).
Figure 4. Tamoxifen interferes with TGF-b1-induced E-cadherin mRNA down-regulation and blocks the induction of Snail mRNA.
Omentum-derived MCs were treated or not with 1 ng/mL TGF-b1 for 12 or 24 hours, in the presence of different doses of Tamoxifen (0, 3 and 6 mM).
(A) Quantitative RT-PCR demonstrates that Tamoxifen treatments prevent TGF-b1-induced E-cadherin mRNA down-regulation. (B) Quantitative RT-
PCR shows that Tamoxifen blocks TGF-b1-mediated induction of Snail mRNA, the main transcriptional repressor of E-cadherin. The expression of E-
cadherin mRNA was analyzed at 24 hours, whereas the expression of Snail mRNA was analyzed at 12 hours of treatments. Bars depict means 6 SE of
three independent experiments.
doi:10.1371/journal.pone.0061165.g004
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Figure 5. Tamoxifen reverts the MMT induced by TGF-b1 in vitro. Omentum-MCs were stimulated with TGF-b1 during 48 hours and then the
cells were either left untreated, treated with TGF-b1 or treated with Tamoxifen (6 or 10 mM) during additional 48 hours. (A) Phase-contrast
microscopy shows that Tamoxifen reverts partially the non-epithelioid morphology of omentum-derived MC treated with TGF-b1. (B) Quantitative
RT-PCR analysis demonstrates that administration of Tamoxifen (6 mM) after TGF-b1 withdrawal restores partially E-cadherin expression. Bar graphic
depicts the expression of E-cadherin-encoding mRNA in relative units (R.U.)
doi:10.1371/journal.pone.0061165.g005
Tamoxifen and Peritoneal Membrane Failure
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Tamoxifen ameliorates peritoneal alterations induced by
dialysis fluid exposure in a mouse PD model
We analyzed whether Tamoxifen might prevent the deteriora-
tion of the PM in a mouse model of PD fluid exposure.
Histological analysis of parietal peritoneum biopsies from animals
exposed to PD fluid (PDF group, n = 14) showed a loss of MCs
monolayer and increased PM thickness when compared with mice
exposed to saline solution (Control group, n = 9) (Figures 8A and
8B). Oral administration of Tamoxifen (1.5 mg/kg/day) to PD
fluid-treated mice (PDF + Tamoxifen group, n = 17) significantly
Figure 6. Tamoxifen reverts partially the mesenchymal phenotype of effluent-derived MCs. Effluent-derived MCs with mesenchymal
phenotype (as determined by non-epitheliod morphology, low expression of E-cadherin and up-regulated expression of mesenchymal markers) were
treated with different doses of Tamoxifen (0, 3, 6, and 10 mM) and analyzed at 48 hours. Omentum-derived MCs were employed as control. (A)
Western blot analyses show that Tamoxifen treatments do not re-induce E-cadherin expression but inhibit the expression of the mesenchymal
molecules a-SMA, collagen I, fibronectin and MMP-2; being the effects of Tamoxifen more evident at high doses (6 and 10 mM). A representative
experiment is shown. (B to F) The experiments were repeated with five different samples of effluent-derived MCs and results of the expression of E-
cadherin (B), a-SMA (C), collagen I (D), MMP-2 (E) and fibronectin (F) are depicted as means 6 SE. Quantitative RT-PCR demonstrates that the
expression of Snail mRNA is not inhibited by any dose of Tamoxifen tested (G). Bars depict means 6 SE of five independent experiments.
doi:10.1371/journal.pone.0061165.g006
Tamoxifen and Peritoneal Membrane Failure
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reduced the peritoneal thickness and preserved the mesothelium
(Figures 8A and 8B).
It has been described that Leptin, a pro-inflammatory
adipocytokine, is able to increase TGF-b1 synthesis and to
cooperate with TGF-b1 in the myofibroblast conversion of MCs.
We found that Tamoxifen had no effect on TGF-b1 concentra-
tions in the PD effluents but it decreased the Leptin levels
(Figures 8C and 8D). These data suggested that Tamoxifen
ameliorated peritoneal thickness by impairing TGF-b1-Leptin
synergism.
Angiogenesis is an important process that occurs in the PM
during PD, and robust anti-angiogenic effect of Tamoxifen has
been described in other tissues. To test the effect of Tamoxifen on
PD fluid-induced angiogenesis, blood vessels of the parietal
peritoneum were stained with an anti-CD31 antibody. As
expected, in the peritoneum from control saline-treated mice the
expression of CD31 was confined to deeper vessels located in the
muscular tissue (Figure 9A). However, there was a significant
increase in the number of submesothelial vessels in PD fluid-
instilled mice when compared with the control mice; and
administration of Tamoxifen to PD fluid-instilled mice significant-
ly reduced this angiogenesis (Figures 9A and 9B). To further
explore the effects of Tamoxifen on angiogenesis, the effluent
levels of VEGF were measured in the different experimental
conditions. PD fluid exposure strongly increased the concentration
of VEGF in the peritoneal cavity, and administration of
Tamoxifen significantly reduced the levels of this factor
(Figure 9C). The protective effects of Tamoxifen described here
had significant implications for the preservation of peritoneal
function. Indeed, Tamoxifen treatment partially preserved the
ultrafiltration capacity of PD fluid-instilled mice (Figure 9D).
Figure 7. Tamoxifen preserves the fibrinolytic capacity of TGF-b1-treated MCs. Omentum-derived MCs were treated or not with 1 ng/mL
TGF-b1 during 48 hours, in the presence of different doses of Tamoxifen (0, 3 and 6 mM). (A to C) Stimulation of MCs with TGF-b1 inhibits the
expression of the fibrinolytic factors uPA (A), uPAR (B) and tPA (C), and treatments with different doses of Tamoxifen restore the basal levels of these
factors or increase their synthesis above basal levels. (D). TGF-b1 treatment increases the expression of PAI-1, and its expression is not affected by
Tamoxifen. The levels of these factors were measured in culture media supernatants by ELISA and results are depicted as nanograms per milligrams
of total cellular proteins (E). The PAI/tPA-ratio, an important marker of fibrinolytic capacity decline, increases in response to TGF-b1 and returns to
basal levels when Tamoxifen is added at 6 mM. Box plots show the 25th and 75th percentiles, median, minimum and maximum values of five
independent experiments. The symbols represent the statistical differences between the groups.
doi:10.1371/journal.pone.0061165.g007
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Tamoxifen reduces PD fluid-induced MMT in vivo
Another characteristic histological change of the peritoneum
during PD is the accumulation of fibroblasts expressing ‘‘fibroblast
specific protein-1’’ (FSP-1) in the submesothelial compact zone,
some of which co-express cytokeratin, indicating their mesothelial
origin via MMT. In order to evaluate the association between
MMT and peritoneal fibrosis progression, we analyzed the
peritoneal tissue of mice exposed to PD fluid during 7, 15 or 30
days. Both Cyto+/FSP-1+ staining and peritoneal fibrosis increased
in a time-dependent manner (Figures 10A to 10C). Furthermore,
MMT and PM fibrosis showed a strong correlation (Figure 10D).
These findings indicated that the MMT was not only an early
phenomenon that triggered the fibrotic process, but rather it
accompanied fibrosis progression until late stages.
Figure 8. Administration of Tamoxifen decreases PD-induced peritoneal membrane thickness in a mouse model. Mice received a daily
instillation of standard PD fluid for 4 weeks with or without the oral administration of Tamoxifen (1.5 mg/kg/day: PDF, n = 14 and PDF + Tamoxifen,
n = 17). A control group of mice that were instilled with saline was also included (Control; n = 9). Peritoneal samples were prepared and analyzed as
described in the Concise Methods. (A) Standard PD fluid exposure increases matrix deposition and the thickness of the peritoneal membrane, while
Tamoxifen administration significantly reduces these effects when measured in Masson’s trichrome stained sections (representative slides).
Magnification6200. (B) The peritoneal thickness ( mm) is increased in DPF group compared with control mice, and the group PDF with Tamoxifen
shows a significant reduction of thickness when compared with PDF group. Analysis of variance results in a significance of p,0.0001 (ANOVA). Box
Plots graphic represent 25th and 75th percentiles, median, minimum and maximum values of thickness ( mm). (C) Measurement of TGF-b1 in the
drained volumes shows an increase of this growth factor in PD fluid-instilled animals and administration of Tamoxifen does not reduce TGF-b1
production. The statistical analysis of variance gives a significance of p= 0.0003. (D) Measurement of leptin in the drained volumes demonstrates an
increase of this adipocytokine in PD fluid-instilled animals and administration of Tamoxifen significantly reduces leptin production, p,0.0001
(ANOVA). Box plots are depicted as picograms per millilitre (pg/mL) and represent the median, minimum and maximum values, as well as the 25th
and 75th percentiles. Numbers above boxes depict means 6 SE. Symbols represent the statistical differences between groups.
doi:10.1371/journal.pone.0061165.g008
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Having shown that MMT is a phenomenon that progresses in
direct proportion to the time on PD and that Tamoxifen blocked
MMT and migration of MCs in vitro, we analyzed whether this
drug also exerted a MMT-blocking effect in vivo in the mouse PD
model (four weeks). As expected, in the peritoneum from control
saline-treated mice, there was no expression of FSP-1 and the
expression of cytokeratin was exclusively restricted to the
preserved mesothelium (Figure 11A). By contrast, in the peritoneal
tissue of PD fluid-instilled mice there was submesothelial
accumulation of FSP-1+ fibroblasts, and a percentage of these
fibroblasts co-expressed cytokeratin (Figures 11A and 11B).
Administration of Tamoxifen to PD fluid-instilled mice signifi-
cantly reduced the total number of FSP-1+ cells, and in particular
of the Cyto+/FSP-1+ subpopulation (Figures 11A and 11B).
Figure 9. Treatment with Tamoxifen decreases PD-induced angiogenesis, inhibits VEGF production and improves peritoneal
ultrafiltration. Mice received a daily instillation of standard PD fluid with or without the oral administration of Tamoxifen (PDF; n = 14 and PDF +
Tamoxifen; n = 17). A control group of mice that were instilled with saline was also included (Control; n = 9). (A) Standard PD fluid exposure increases
peritoneal angiogenesis and Tamoxifen administration significantly reduces the number of vessels, as determined by CD31 staining (representative
slides). Magnification6200. (B) Box plots represent the CD31+ staining in the different experimental groups and show a decrease of angiogenesis in
the Tamoxifen-treated animals. (C) Analysis of VEGF in the drained volumes shows a strong increase of this growth factor in PD fluid-instilled animals,
and administration of Tamoxifen significantly reduces VEGF production. The ANOVA test resulted in a significance of p,0.0001. (D) A 30 minutes
ultrafiltration test was performed on the last day of treatments. The volumes recovered from animals exposed to PD fluid are lower than those from
mice instilled with saline solution and an increase of net ultrafiltration is obtained in mice exposed to PD fluid that were administrated Tamoxifen. A
significance of p,0.0001 was obtained with the analysis of variance test. Box Plots graphics represent 25th and 75th percentiles, median, minimum
and maximum values. Numbers above boxes depict means 6 SE. Symbols represent the statistic differences between groups.
doi:10.1371/journal.pone.0061165.g009
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Figure 10. Parallelism between MMT, PM thickness and time on PD. (A) Immunofluorescence microscopy images of parietal peritoneal
sections stained for cytokeratin (green) and FSP-1 (red), with DAPI counterstaining, show accumulation of trans-differentiated mesothelial cells in the
submesothelial space at 7, 15 and 30 days of PD mice. Progressive time-dependent increases of MMT and PM thickness is observed during PD fluid
exposure. Representative slides are presented. Magnification6200. (B) Quantification of the submesothelial MMT (cytokeratin/FSP-1 double positive
cells per field) at different time points. (C) Quantification of peritoneal thickness ( mm) at different time points. Box Plots represent 25% and 75%
percentiles, median, minimum and maximum values. Numbers above boxes depict means 6 SE. Symbols show statistical differences between
groups. (D) Correlation between both MMT and peritoneal thickness was determined by Spearman regression analysis.
doi:10.1371/journal.pone.0061165.g010
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Figure 11. Effects of Tamoxifen on the number of fibroblasts derived from MCs. (A) Immunofluorescence microscopy analysis of parietal
peritoneal sections stained for cytokeratin (green) and FSP-1 (red) with DAPI counterstaining show accumulation of trans-differentiated mesothelial
cells in the submesothelial space (cytokeratin positive cells) in the PDF group, some of which co-express FSP-1 (yellow cells in the Merge panel). The
administration of Tamoxifen reduces the number of cytokeratin/FSP-1 double positive cells per field. Representative slides are presented.
Magnification6200. (B) Reductions of the number of cytokeratin/FSP-1 positive fibroblasts by Tamoxifen are significant. Box Plots represent 25% and
75% percentiles, median, minimum and maximum values. Numbers above boxes depict means 6 SE. Symbols show statistical differences between
groups.
doi:10.1371/journal.pone.0061165.g011
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Discussion
Sclerotic peritonitis syndromes (SPS) includes a wide range of
peritoneal fibrosis that develops progressively during PD treatment
and reaches severe fibrosis in 40 to 70% of cases. SPS has been
traditionally considered a reversible condition, while EPS still
progresses even after the interruption of PD treatment [4].
Although the pathways to reach EPS from SPS have not been fully
established, emerging evidences have indicated that MMT is
persistently present in initial and end-stages of peritoneal fibrosis
[1], [8], [34]. In this study, we demonstrate that MMT progresses
in parallel with peritoneal fibrosis in the mouse PD model.
Tamoxifen has been extensively used for the treatment of
advanced fibrotic disorders, but there are only few data about
his beneficial effect on the prevention or blockade of fibrosis at
early stages. In this context, it has been recently shown that
Tamoxifen treatment protects from renal fibrosis in a rat model of
hypertensive nephrosclerosis [19]. Herein, we explored the effects
of Tamoxifen on early stages of peritoneal fibrosis induced by PD.
Given the central role of the MMT process in the initiation and
progression of peritoneal injury in PD patients [7], [8], [34], we
have analyzed the effects of Tamoxifen on the MMT of MCs in
vitro and in a mice PD model. We found that Tamoxifen is able to
block and to revert the MMT of MCs induced by TGF-b1 and
that this drug partially reverts the mesenchymal phenotype of
effluent-derived MCs. Although Tamoxifen may also act on cells
lacking estrogen receptors [35], herein we confirmed the presence
of a-ER in MCs, the expression of which increased in response to
administration of Tamoxifen and/or TGF-b1. Tamoxifen was
initially described as an anti-estrogen drug, however more
recently, in agreement with our results it has been shown that
Tamoxifen may also act as an agonist of the a-ER in some cell
types, such as endothelial cells [36]. In fact, in transdifferentiated
MCs from PD effluent the a-ER is highly expressed and
Tamoxifen further increases this expression (Figure 1).
Of note, Tamoxifen blocks TGF-b1-induced down-regulation
of E-cadherin and up-regulation of the transcriptional repressors
Snail in a context of high expression levels of a-ER (Figures 1 and
4). This is in good agreement with results obtained in breast cancer
cells, in which the over-expression of exogenous a-ER induced E-
cadherin and down-regulated the expression of Snail, and clones
exhibiting these changes grew in clumps and became less invasive
[37]. Conversely, when a-ER was knocked down in a-ER-positive
breast cancer cell lines, Snail increased, E-cadherin decreased and
cells became spindle-shaped and exhibited increased migratory/
invasive capacity [37]. In this context, we observed that MCs
treated with TGF-b1 acquire increased migratory capacity, and
that Tamoxifen treatments reduce this capacity, probably by
blocking MMP-2 expression.
As a consequence of its ability to block and to revert the MMT
process, Tamoxifen-treatment decreases the production of extra-
cellular matrix components (collagen I and fibronectin) and
preserves the fibrinolytic capacity of MCs, which could explain the
anti-fibrotic effect exerted by this drug on the PM. Herein, we
demonstrate that Tamoxifen ameliorates peritoneal thickness and
decreases submesothelial accumulation of transdifferentiated MCs
in PD fluid-instilled mice. Our results suggest a dual anti-fibrotic
effect of Tamoxifen on MMT in vivo: 1.- direct blocking of the
MMT process itself, and 2.- inhibition of leptin expression, and
therefore impeding the TGF-b1-leptin cooperation in the induc-
tion of MMT and fibrosis. In this context, it has been shown that
peritoneal adipocytes exposed to glucose from PD liquids produce
leptin, which in turn promotes TGF-b1 production by MCs and
cooperates with TGF-b1 in the induction of MMT of MCs [38],
[39]. In concordance with our results, it has recently been reported
that Tamoxifen can reduce circulating levels of leptin [40],
although this results remains to be confirmed [41], [42], seems
clear that leptin is a key molecule in the induction MMT, tissue
fibrosis and angiogenesis. Another possible anti-fibrotic mecha-
nism associated with Tamoxifen could be the down-regulation of
the pro-fibrotic connective tissue growth factor (CTGF) [17].
Angiogenesis is an important sign of type-I PM failure and we
demonstrate that Tamoxifen decreases the number of subme-
sothelial vessels in mice peritoneal tissue exposed to PD fluid,
which may be due to Tamoxifen-mediated down-regulation of
VEGF expression in the effluents. This anti-angiogenic effect
could also be due to a reduction of leptin levels, given that both
molecules may act in a cooperative manner to induce neovascu-
larization [43]. Importantly, this vessels reduction resulted in the
maintenance of the UF capacity reinforcing the idea that increase
in peritoneal vessels number are key in the hyperfiltration
associated to type-I PM failure.
The robustness of our results in both in-vivo and in-vitro together
with previous clinical studies invite to use Tamoxifen in SPS to
prevent the type-I PM failure. Our clinical experience with
Tamoxifen for the treatment of EPS started in 1992 after the
positive results of Clark et al. using Tamoxifen to treat
retroperitoneal fibrosis [14]. We demonstrated a significant
improvement in survival and a reduction of abdominal compli-
cations in nine patients with EPS orally treated with Tamoxifen
[15]. Afterwards we extended our study by including five
additional patients and by expanding the time of follow-up, which
confirmed the beneficial effects of Tamoxifen in terms of
abdominal complications, hospital admissions and mortality (data
not shown). Recently, Korte et al. published the results of the
Multicenter Dutch EPS study, which concluded that almost from
the start of the study the group treated with Tamoxifen showed
better survival than non-treated group [16]. Thus, there is
increasing evidence about the benefic effect of Tamoxifen for
treating retroperitoneal fibrosis and EPS alone or in combination
with immunosuppressant drugs [12].
In conclusion, it is tempting to hypothesize that MMT,
peritoneal fibrosis and EPS may be part of the same patho-
physiologic process and therefore, Tamoxifen exerts a protective
effects on the peritoneal membrane during both early and late
stages of fibrotic disorders. Following exposure to PD fluids,
Tamoxifen protects the peritoneum by inhibiting the production
of matrix components, leptin, and VEGF, and maintaining the
fibrinolytic capacity. Together these effects, Tamoxifen contribute
to the anti-MMT, anti-fibrotic and anti-angiogenic activities
observed.
Supporting Information
Figure S1 Effect of Tamoxifen on MCs apoptosis in
vitro. MCs were cultured to subconfluence and rested for
24 hours. The cells were pre-incubated with Tamoxifen (3, 6 and
10 mM) for one hour and treated with 100 nM Staurosporine
(STS) for 24 hours. Flow cytometry assessment of DNA content
shows that treatment with different doses of Tamoxifen decreases
apoptosis of cells treated with STS. Bars depict the means6 SD of
three independent experiments performed in triplicate and the
symbol represents the statistical differences.
(TIF)
Figure S2 Effect of Tamoxifen on the wound repair
capacity of MCs. Omentum-derived MCs, administered
Tamoxifen (3 and 6 mM) or not, were subjected to mechanical
injury and photographed every twelve hours over 72 hours. MCs
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treated with 6 mM of Tamoxifen showed a slight delay at 24 and
48 hours in closing the wound. However, at 72 hour there were
minimal differences between cells treated or not with Tamoxifen.
(TIF)
Figure S3 Tamoxifen does not modify the PAI/tPA-ratio
in transdifferentiated MCs from PD effluent. Non-
epitheliod effluent-derived MCs were treated with Tamoxifen (3,
6 and 10 mM) during 48 h. The levels of PAI-1 and tPA were
measured in culture media supernatants by ELISA. Results show
that Tamoxifen does not modify the PAI-1/tPA-ratio.
(TIF)
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